Zhongsheng Beikong Biotechnology Co., Ltd. (“Zhongsheng Beikong” or the “Company”) is a leading supplier of in vitro diagnostic (“in vitro diagnosis”) reagents in the People's Republic of China (“China”). The Company and its subsidiaries (collectively, the “Group”) are mainly engaged in the development, production, sale and distribution of in vitro diagnostic reagent products, and provide high-quality and reliable disease detection reagent products for hospitals and other medical institutions.
The company's main equity holders have strong backgrounds. The largest shareholder, Beijing Saipu Asset Management Co., Ltd., is a wholly-owned subsidiary of the Institute of Biophysics (“Institute of Biophysics”) of the Chinese Academy of Sciences (“Chinese Academy of Sciences”). The Biophysics Institute is one of the most authoritative research institutes in life sciences in China; Beijing Holdings Co., Ltd. (“Beijing Holdings”), the second largest shareholder, is a company incorporated in Hong Kong, and its shares are listed on the main board of the Stock Exchange (stock code: 0392). Beijing Holdings, along with its subsidiaries, is mainly engaged in natural gas business, beer business, sewage treatment and water business, and solid waste treatment business in China.
The Group's brand “Zhongsheng” is famous in the industry. “Zhongsheng” was awarded the “Beijing Famous Brand Product” award in 2002, the “No.1 Brand for User Satisfaction Quality and Reputation in the Chinese Diagnostic Reagent Market” award in 2005, and won the title of “Famous Trademark of Beijing”, which is widely recognized by market users and the medical community. Adopting a marketing model combining direct sales and distributors, the Group has established an efficient, stable marketing network covering more than 600 distributors in more than 30 provinces, municipalities and autonomous regions across the country. The Group's diagnostic reagent products are widely sold in domestic hospitals and medical institutions.
In addition, the Group's management includes a number of university professors and PhDs, who have continuously strengthened the Group's overall competitiveness based on the business policy of “putting people first, advocating innovation, quality first, and pursuing perfection, honest labor and legal operation”. Many of these managers have carried out research work in biophysics. Their strong scientific research backgrounds and ambitions have laid a good research foundation for Zhongsheng Beijing Holdings and also helped the long-term development of the Group's business.
The Company's H shares have been listed on GEM since February 27, 2006.
CEO： Lebin Wu
Listing Date： 02/27/2006